1,5-Dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole, 95.0%, 5g

2-(Chloromethyl)quinoline, 95.0%, 25g

L-Seryl-L-phenylalanyl-L-leucyl-L-leucyl-L-arginyl-L-asparagine, 98%, 10mg

2-(P-tolyl)-1,3-dithiane, 98%, 5g

(7aR)-7a-Methyl-2,3,6,7-tetrahydroindene-1,5-dione, 97%, 1g

Di-tert-butyl(2',4',6'-triisopropyl-3,6-dimethoxy-[1,1'-biphenyl]-2-yl)phosphine, 97%, 1g

Recipiente de evaporación ROTILABO® forma inferior, 75 ml, 1 Pieza

Tert-butyl(5r)-3,3-difluoro-5-hydroxy-piperidine-1-carboxylate, 98%, 500mg

ETHYL 2-(5-BROMO-3-NITROPYRIDIN-2-YL)ACETATE, 95.0%, 1g

2-Chloro-4-fluorobenzonitrile>98.0%(GC)25g

1-methyl-1H-pyrazol-4-ol, 95.0%, 1g

Quinoline-6-sulfonyl chloride, 95.0%, 2.5g

(R)-3-((1-PHENYLETHYL)AMINO)CYCLOHEX-2-ENONE, 95.0%, 500mg